These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 35241046)

  • 1. Dynamic changes in the systemic immune-inflammation index predict the prognosis of EGFR-mutant lung adenocarcinoma patients receiving brain metastasis radiotherapy.
    Wang Q; Tan X; Deng G; Fu S; Li J; Li Z
    BMC Pulm Med; 2022 Mar; 22(1):75. PubMed ID: 35241046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-radiotherapy systemic immune inflammation index associated with overall survival in patients with advanced EGFR mutant non-small cell lung cancer receiving thoracic radiotherapy.
    Chen D; Qin H; Deng G; Wang Q; Wang H; Liu X
    Clin Transl Oncol; 2023 Jan; 25(1):226-235. PubMed ID: 36070068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy.
    Zhou Y; Li J; Li Y; Deng G; Wang Q; Qin H; Li J; Li Z
    Clin Transl Oncol; 2024 Aug; 26(8):1968-1975. PubMed ID: 38478262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
    Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
    Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of the systemic immune-inflammation index in brain metastases from lung adenocarcinoma with different EGFR mutations.
    Li H; Wang G; Zhang H; Song X; Cao J; Zhang X; Xue R; Wang W; Jia S; Li Z
    Genes Immun; 2019 Jul; 20(6):455-461. PubMed ID: 30410015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of brain radiotherapy strategies on prognosis of patients with EGFR-mutant lung adenocarcinoma with brain metastasis.
    Deng G; Zhang Y; Ke J; Wang Q; Qin H; Li J; Li Z
    J Transl Med; 2021 Nov; 19(1):486. PubMed ID: 34847914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
    Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
    Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs.
    Deng C; Zhang N; Wang Y; Jiang S; Lu M; Huang Y; Ma J; Hu C; Hou T
    Medicine (Baltimore); 2019 Aug; 98(33):e16875. PubMed ID: 31415428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Therapies and Utility of the Lung-molGPA in Non-Small-Cell Lung Cancer Patients with Brain Metastases.
    Cacho-Díaz B; Cuapantécatl LD; Garcilazo-Reyes YJ; Cabrera-Miranda L; Hernandez-Martinez JM; Arrieta O
    Oncology; 2022; 100(10):542-554. PubMed ID: 35988535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High systemic immune-inflammation index is a predictor of poor prognosis in patients with nonsmall cell lung cancer and bone metastasis.
    Xu S; Cao S; Yu Y
    J Cancer Res Ther; 2021 Dec; 17(7):1636-1642. PubMed ID: 35381733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients.
    Hsiao SH; Lin HC; Chou YT; Lin SE; Kuo CC; Yu MC; Chung CL
    Lung Cancer; 2013 Sep; 81(3):455-461. PubMed ID: 23871711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical study.
    Liu S; Qiu B; Chen L; Wang F; Liang Y; Cai P; Zhang L; Chen Z; Liu S; Liu M; Liu H
    Radiat Oncol; 2015 May; 10():118. PubMed ID: 26014133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis.
    Chen Y; Wei J; Cai J; Liu A
    BMC Cancer; 2019 Aug; 19(1):793. PubMed ID: 31399067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implications of systemic immune-inflammation index in patients with bone metastases from hepatocellular carcinoma treated with radiotherapy.
    Chen J; Huang W; Xu X; Fan S; Zhang Q; Li X; Zeng Z; He J
    Front Oncol; 2023; 13():1076428. PubMed ID: 37251953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of EGFR/ALK alterations in leptomeningeal metastasis from lung adenocarcinoma treated with whole-brain radiotherapy.
    Oyoshi H; Hirata H; Hirano Y; Zenda S; Zhou Y; Tomizawa K; Fujisawa T; Nakamura M; Hojo H; Motegi A; Kageyama SI; Zenke Y; Goto K; Ishihara S; Naganawa S; Akimoto T
    Clin Exp Metastasis; 2023 Oct; 40(5):407-413. PubMed ID: 37468822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of thoracic radiotherapy dose on the prognosis of advanced lung adenocarcinoma harboring EGFR mutations.
    Qin H; Ke J; Dong S; Li H; Zhu K; Fu S; Shao Q; Li Z
    BMC Cancer; 2022 Sep; 22(1):1012. PubMed ID: 36153486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.
    Ke SB; Qiu H; Chen JM; Shi W; Chen YS
    Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic values of systemic immune-inflammation index and derived neutrophil-lymphocyte ratio in EGFR-mutant advanced non-small cell lung cancer.
    Yucel S; Bilgin B
    J Oncol Pharm Pract; 2021 Jan; 27(1):71-77. PubMed ID: 32248739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?
    Han G; Bi J; Tan W; Wei X; Wang X; Ying X; Guo X; Zhou X; Hu D; Zhen W
    Oncotarget; 2016 Aug; 7(35):56998-57010. PubMed ID: 27486770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.